BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 18519753)

  • 1. Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors.
    Steffensen KD; Waldstrøm M; Olsen DA; Corydon T; Lorentzen KA; Knudsen HJ; Jeppesen U; Brandslund I; Jakobsen A
    Clin Cancer Res; 2008 Jun; 14(11):3278-82. PubMed ID: 18519753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulation of integrin alpha2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation.
    Ning Y; Zeineldin R; Liu Y; Rosenberg M; Stack MS; Hudson LG
    Cancer Res; 2005 Oct; 65(20):9280-6. PubMed ID: 16230389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesenchymal transformation in epithelial ovarian tumor cells expressing epidermal growth factor receptor variant III.
    Zeineldin R; Rosenberg M; Ortega D; Buhr C; Chavez MG; Stack MS; Kusewitt DF; Hudson LG
    Mol Carcinog; 2006 Nov; 45(11):851-60. PubMed ID: 16788982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of Epidermal Growth Factor Receptor variant III in laryngeal carcinoma tissues.
    Yang B; Chen J; Zhang X; Cao J
    Auris Nasus Larynx; 2009 Dec; 36(6):682-7. PubMed ID: 19427146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.
    Blehm KN; Spiess PE; Bondaruk JE; Dujka ME; Villares GJ; Zhao YJ; Bogler O; Aldape KD; Grossman HB; Adam L; McConkey DJ; Czerniak BA; Dinney CP; Bar-Eli M
    Clin Cancer Res; 2006 Aug; 12(15):4671-7. PubMed ID: 16899617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.
    Lammering G; Hewit TH; Holmes M; Valerie K; Hawkins W; Lin PS; Mikkelsen RB; Schmidt-Ullrich RK
    Clin Cancer Res; 2004 Oct; 10(19):6732-43. PubMed ID: 15475464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of the type III epidermal growth factor receptor mutation in colorectal cancer.
    Spindler KL; Olsen DA; Nielsen JN; Brandslund I; Poulsen HS; Villingshøj M; Jakobsen A
    Anticancer Res; 2006; 26(6C):4889-93. PubMed ID: 17214357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
    Ramnarain DB; Park S; Lee DY; Hatanpaa KJ; Scoggin SO; Otu H; Libermann TA; Raisanen JM; Ashfaq R; Wong ET; Wu J; Elliott R; Habib AA
    Cancer Res; 2006 Jan; 66(2):867-74. PubMed ID: 16424019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFRvIII mutation in lung cancer correlates with increased EGFR copy number.
    Sasaki H; Kawano O; Endo K; Yukiue H; Yano M; Fujii Y
    Oncol Rep; 2007 Feb; 17(2):319-23. PubMed ID: 17203167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma.
    Foster JM; Gatalica Z; Lilleberg S; Haynatzki G; Loggie BW
    Ann Surg Oncol; 2009 Jan; 16(1):152-8. PubMed ID: 18998063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of a truncated epidermal growth factor receptor-like protein (TEGFR) in ovarian cancer.
    Ilekis JV; Gariti J; Niederberger C; Scoccia B
    Gynecol Oncol; 1997 Apr; 65(1):36-41. PubMed ID: 9103388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients.
    Heimberger AB; Hlatky R; Suki D; Yang D; Weinberg J; Gilbert M; Sawaya R; Aldape K
    Clin Cancer Res; 2005 Feb; 11(4):1462-6. PubMed ID: 15746047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors.
    Steffensen KD; Waldstrøm M; Andersen RF; Olsen DA; Jeppesen U; Knudsen HJ; Brandslund I; Jakobsen A
    Int J Oncol; 2008 Jul; 33(1):195-204. PubMed ID: 18575766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer.
    Azuma M; Danenberg KD; Iqbal S; El-Khoueiry A; Zhang W; Yang D; Koizumi W; Saigenji K; Danenberg PV; Lenz HJ
    Clin Colorectal Cancer; 2006 Sep; 6(3):214-8. PubMed ID: 17026791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma.
    Hama T; Yuza Y; Saito Y; O-uchi J; Kondo S; Okabe M; Yamada H; Kato T; Moriyama H; Kurihara S; Urashima M
    Oncologist; 2009 Sep; 14(9):900-8. PubMed ID: 19726454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The deletion mutant EGFRvIII significantly contributes to stress resistance typical for the tumour microenvironment.
    Theys J; Jutten B; Dubois L; Rouschop KM; Chiu RK; Li Y; Paesmans K; Lambin P; Lammering G; Wouters BG
    Radiother Oncol; 2009 Sep; 92(3):399-404. PubMed ID: 19616331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of collapsin response mediator Protein1, as detected by iTRAQ analysis, promotes invasion of human gliomas expressing mutant EGFRvIII.
    Mukherjee J; DeSouza LV; Micallef J; Karim Z; Croul S; Siu KW; Guha A
    Cancer Res; 2009 Nov; 69(22):8545-54. PubMed ID: 19903856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer.
    Olapade-Olaopa EO; Moscatello DK; MacKay EH; Horsburgh T; Sandhu DP; Terry TR; Wong AJ; Habib FK
    Br J Cancer; 2000 Jan; 82(1):186-94. PubMed ID: 10638988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGF receptor variant III as a target antigen for tumor immunotherapy.
    Li G; Wong AJ
    Expert Rev Vaccines; 2008 Sep; 7(7):977-85. PubMed ID: 18767947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study on the expression and mutation of cadherin 6 gene in human ovarian carcinoma].
    Li DR; Li L; Zhang W; Wang LM; Zhang JQ
    Zhonghua Fu Chan Ke Za Zhi; 2004 Sep; 39(9):616-9. PubMed ID: 15498191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.